(Q35129039)

6 August 2017

1 reference

title

Clinical pharmacology of antifungal compounds (English)

1 reference

6 August 2017

6

Thomas J Walsh

1 reference

6 August 2017

5

Georg Maschmeyer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12751265

3 January 2024

author name string

Axel Glasmacher

3

1 reference

6 August 2017

Gudrun Just-Nuebling

4

1 reference

6 August 2017

Andreas H. Groll

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12751265

3 January 2024

Juan C. Gea-Banacloche

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12751265

3 January 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12751265

3 January 2024

publication date

1 March 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0891552002000685?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(02)00068-5

https://api.elsevier.com/content/article/PII:S0891552002000685?httpAccept=text/plain

3 January 2024

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(02)00068-5

Infectious Disease Clinics of North America

3 January 2024

published in

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

159-91, ix

1 reference

Amphotericin B: current understanding of mechanisms of action

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Uncommon opportunistic fungi: new nosocomial threats

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Amphotericin B Pharmacokinetics in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Distribution and activity of amphotericin B in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Clinical pharmacokinetics of systemic antifungal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Lipid formulations of amphotericin B: recent progress and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Lipid formulations of amphotericin B: clinical efficacy and toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Safety of amphotericin B colloidal dispersion

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Flucytosine: correlation between toxicity and pharmacokinetic parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Effect of fluconazole on viability of Candida albicans over extended periods of time

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Safety and pharmacokinetics of fluconazole in children with neoplastic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Oral azole drugs as systemic antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Safety and tolerability of fluconazole in children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Antifungal agents: an overview. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Hepatosplenic candidiasis: successful treatment with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Pharmacology of itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Adverse events associated with itraconazole in 189 patients on chronic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Congestive heart failure associated with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Treatment of invasive aspergillosis with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Itraconazole treatment of phaeohyphomycosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Itraconazole therapy in lymphangitic and cutaneous sporotrichosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

New drugs and novel targets for treatment of invasive fungal infections in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Novel triazole antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Lipopeptide inhibitors of fungal glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900068-5

7 January 2021

Antifungal drug resistance in pathogenic fungi

5

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(02)00068-5

Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis

3 January 2024

24

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(02)00068-5

Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature

3 January 2024

28

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(02)00068-5

1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus

3 January 2024

76

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(02)00068-5

Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS

3 January 2024

104

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(02)00068-5

3 January 2024

Identifiers

1 reference

6 August 2017

1 reference